MedTrace Logo

A Study to Evaluate Camoteskimab in Participants With Still's Disease

NCT04752371 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-08-23

No results posted yet for this study

Summary

The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.

Conditions

  • Adult Onset Still's Disease

Interventions

DRUG

Camoteskimab (CERC-007, AVTX-007, AEVI-007)

Intravenous (IV) Infusion

Sponsors & Collaborators

  • Apollo Therapeutics Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-25
Primary Completion
2022-05-24
Completion
2022-05-24
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Poland
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752371 on ClinicalTrials.gov